Helicobacter pylori-related diseasess;Enfermedades relacionadas con la infección por Helicobacter pylori

Gastroenterologia y Hepatologia

Volumn 35, Issue SUPPL. 1, 2012, Pages 12-25

  Gisbert, Javier P ^a,b  

^a Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Diagnosis; Dyspepsia; Gastric cancer; Helicobacter pylori; Peptic ulcer; Treatment

Indexed keywords

BISMUTH; LEVOFLOXACIN; MOXIFLOXACIN; SITAFLOXACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; DEVELOPING COUNTRY; DYSPEPSIA; ENDOSCOPIC SURGERY; ERADICATION THERAPY; FOLLOW UP; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIGH RESOLUTION ENDOSCOPY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INCIDENCE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NARROW BAND IMAGING; NONHUMAN; PEPTIC ULCER; PRESCRIPTION; PREVALENCE; SPAIN; STOMACH CANCER;

ADENOCARCINOMA; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; STOMACH NEOPLASMS;

EID: 84866775230     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/S0210-5705(12)70030-4     Document Type: Article

References (94)

1. Kusakari M., Nakayama Y., Horiuchi A., Hirashima S., Shima Y., Kato S., et al. The dramatic change of gastointestinal disorders in Japanese children and adolescents over the last decade. Gastroenterology 2012, 142(Suppl 1):S-711.
2. Bures J., Kopacova M., Koupil I., Seifert B., Skodova Fendrichova M., Spirkova J., et al. Epidemiology of Helicobacter pylori in the Czech Republic Significant decrease in prevalence within a 10- year period. Gastroenterology 2012, 142(Suppl 1):S-480.
3. Gisbert J.P., McNicholl A.G. Helicobacter pylori infection in Spain: is its prevalence really decreasing?. Gastroenterology 2012, 142(Suppl 1):S-482.
4. Porras C., Nodora J., Sexton R., Domínguez R., Jiménez S., Anderson G.L., et al. Risk factors for Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701). Gastroenterology 2012, 142(Suppl 1):S-480.
5. Tsukanov V.V., Amelchugova O.S., Vasyutin A.V., Tretyakova O.V. Prevalence and risk factors of uninvestigated dyspepsia and atrophic gastritis in the urban population of Siberia over 45 years old. Gastroenterology 2012, 142(Suppl 1):S-467.
6. Gisbert J.P., Pajares J.M. Helicobacter pylori " rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002, 16:1047-1057.
7. Megraud F., Coenen S., Versporten A., Kist M., López-Brea M., Hirschl A., et al. Helicobacter pylori Resistance to Antibiotics in Europe and Its Relationship to Antibiotic Consumption. Gastroenterology 2012, 142(Suppl 1):S-146.
8. Malfertheiner P., Megraud F., O'Morain C.A., Atherton J., Axon A.T., Bazzoli F., et al. Management of Helicobacter pylori infection- the Maastricht IV/Florence Consensus Report. Gut 2012, 61:646-664.
9. Gisbert J.P., Calvet X., Gomollon F., Sainz R. Treatment for the eradication of Helicobacter pylori Recommendations of the Spanish Consensus Conference. Med Clin (Barc) 2000, 114:185-195.
10. Domínguez R., Morgan D.R., Sexton R., Pena E.M., Greenberg E.R., Rollan A., et al. ROME III criteria-based prevalence of dyspepsia symptoms in general populations in six countries in Latin America (SWOG Trial S0701). Gastroenterology 2012, 142(Suppl 1):S-465.
11. Moayyedi P., Soo S., Deeks J., Delaney B., Harris A., Innes M., et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006, CD002096.
12. Wang Y., Zhou L., Meng L., Lin S. Effect of the Helicobacter pylori eradication on patients with different subtype of functional dyspepsia: a randomized control trial. Gastroenterology 2012, 142(Suppl 1):S-843.
13. Gisbert J.P., Blanco M., Mateos J.M., Fernández-Salazar L., Fernández- Bermejo M., Cantero J., et al. H. pylori-negative duodenal ulcer prevalence and causes in 774 patients. Dig Dis Sci 1999, 44:2295-2302.
14. Gisbert J.P., Calvet X. Helicobacter pylori-negative duodenal ulcer disease. Aliment Pharmacol Ther 2009, 30:791-815.
15. Gopal P., Cathomas G., Genta R.M. The prevalence of H. pylorinegative gastric and duodenal ulcers in the united states greatly exceeds that of H. pylori-positive ulcers. Gastroenterology 2012, 142(Suppl 1):S-474.
16. Chng J., Kian Ch'ng J., Keong Wong W., Ling K.L. Helicobacter pylori-Negative, non-NSAID related peptic ulcer disease: profiling the patients with this disease. Gastroenterology 2012, 142(Suppl 1):Sa1662.
17. Sadjadi Al, Alizadeh B.Z., Babaei M., Derakhshan M.H., Ahmadi E., Etemadi A., et al. Helicobacter pylori infection and development of gastric cancer a 10-year follow-up population-based study in a high incidence area. Gastroenterology 2012, 142(Suppl 1):S-630.
18. Wong B.C., Lam S.K., Wong W.M., Chen J.S., Zheng T.T., Feng R.E., et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004, 291:187-194.
19. De Vries A.C., Holster I.L., Kuipers E.J. Cochrane Review: Helicobacter pylori eradication for pre-malignant lesions of the gastric mucosa. Gastroenterology 2012, 142(Suppl 1):S-633.
20. Kodama M., Murakami K., Okimoto T., Shiota S., Nakagawa Y., Mizukami K., et al. Long term prospective follow-up of histological alteration at 5 points on the gastric mucosa recommended by the updated sydney system after Helicobacter pylori eradication. Gastroenterology 2012, 142(Suppl 1):S-477.
21. Sugimoto T., Yamaji Y., Sakitani K., Isomura Y., Yoshida S., Yamada A., et al. Metachronous gastric cancer risk after endoscopic submucosal dissection. Gastroenterology 2012, 142(Suppl 1):S-630.
22. Kato M., Asaka M., Kikuch S. Long-term follow-up study about preventive effect of h. pylori eradication for the incidence of metachronous gastric cancer after endoscopic resection of primary early gastric cancer. Gastroenterology 2012, 142(Suppl 1):S-3.
23. Eun Bae S., Jung H.Y., Jung J.H., Hoon Kim D., Yong Ahn J., Choi K.S., et al. Effect of eradication of Helicobacter pylori on recurrence after endoscopic resection of gastric adenoma and early gastric cancer. Gastroenterology 2012, 142(Suppl 1):S-183.
24. Chon I., Ho Lee D., Kim N., Hyub Lee S., Choi C. Effect of Helicobacter pylori eradication on subsequent dysplasia development after endoscopic resection of gastric dysplasia. Gastroenterology 2012, 142(Suppl 1):Sa1638.
25. Choi J.H., Gyun Kim S., Pil Im J., Sung Kim J., Chae Jung H. Helicobacter pylori eradication after endoscopic resection of gastric tumors. Gastroenterology 2012, 142(Suppl 1):S-489.
26. Gisbert J.P., Calvet X. Common misconceptions in the management of Helicobacter pylori-associated gastric MALT-lymphoma. Aliment Pharmacol Ther 2011, 34:1047-1062.
27. Okada S., Suzuki H., Matsuzaki J., Tsugawa H., Fukuhara S., Hirata K., et al. The extension of mucosal lesions Helicobacter pylori Infection status and API2-MALT1 positivity are associated with the therapeutic response for gastric MALT lymphoma. Gastroenterology 2012, 142(Suppl 1):S-760.
28. Okada H., Kawahara Y., Nasu J., Kawano S., Tsuzuki T., Kita M., et al. Efficacy and long-term follow-up of Helicobacter pylori eradication therapy and radiation therapy as a secondary treatment for localized gastric mucosa-associated lymphoid tissue lymphoma. Gastroenterology 2012, 142(Suppl 1):S-215.
29. Kondo S., Niwa Y., Tajika M., Tanaka T., Mizuno N., Hara K., et al. Feasibility of watch-and-wait strategy for histological relapse of gastric MALT lymphoma after Helicobacter pylori eradication therapy. Gastroenterology 2012, 142(Suppl 1):S-761.
30. Kawakami E., Hanai Brito H.S., Braga J.P., Machado R.S., Loggetto S.R., Granato C. Helicobacter pylori infection and chronic thrombocytopenic purpura in children and adolescents - a randomized controlled trial. Gastroenterology 2012, 142(Suppl 1):S-184.
31. Zagari R.M., Eusebi L.H., Rabitti S., Bazzoli F. Accuracy of Gastro- Panel for the diagnosis of atrophic gastritis: a meta-analysis. Gastroenterology 2011, 142(Suppl 1):S-403.
32. Dalal K., Zhang X., González-Haba Ruiz M., Westerhoff M., Reddy K.G., Hart J., et al. Conventional narrow band imaging for the improved detection of gastritis. Gastroenterology 2012, 142(Suppl 1). Sa1721.
33. Luna P., Pereyra L., Casas G.L., Mella J.M., Mohaidle A., González R., et al. Is it possible to identify normal gastric mucosa Helicobacter pylori infected mucosa and gastric intestinal metaplasia by using narrow band imaging endoscopy without magnification? a prospective study. Gastroenterology 2012, 142(Suppl 1). Tu1670.
34. Cho J.H., Jang J.Y., Chang Y.W. Real-time detection of Helicobacter pylori by high-definition endoscopy is possible within the gastric corpus. Gastroenterology 2012, 142(Suppl 1). Sa1657.
35. Neumann H., Foertsch S., Ritter B., Vieth M., Kuth R., Neurath M.F. Final Data of a new electrochemical device that enables rapid and accurate detection of Helicobacter pylori infection. Gastroenterology 2012, 142(Suppl 1):S-484.
36. O'Donovan M., Lao-Sirieix P., Fitzgerald R. Non-endoscopic diagnostic tests for esophageal diseases and H. pylori using the cytosponge. Gastroenterology 2012, 142(Suppl 1):S-421.
37. Kwon C.I., Gyung Seon H., Pil Yun S., Yoon H., Guil Lee J., Hyun Ko K., et al. Tailored therapy based on Dpo Multiplex PCR improves Helicobacter pylori eradication rate. Gastroenterology 2012, 142(Suppl 1):S-484.
38. Gisbert J.P., Calvet X. The effectiveness of standard triple-therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Gastroenterology 2012, 142(Suppl 1):S-481-S-482.
39. Gisbert J.P., Calvet X. The effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011, 34:1255-1268.
40. Gisbert J.P., McNicholl A.G. Maintenance of Helicobacter pylori eradication rates with triple therapy over 12 years in a Spanish hospital. Gastroenterology 2012, 142(Suppl 1):S-481.
41. Gisbert J.P., McNicholl A.G. Maintenance of Helicobacter pylori eradication rates with triple therapy over 12 years in a Spanish hospital. Helicobacter 2012, 17:160-161.
42. Hoon Yoon J., Ho Baik G., Yong Kim D., Soo Kim Y., Tae Suk K., Bong Kim J., et al. The trend of eradication rates of first- and secondline therapy for Helicobacter pylori infection: single center experience for recent eleven years. Gastroenterology 2012, 142(Suppl 1):S-478.
43. Villoria A., García P., Calvet X., Gisbert J.P., Vergara M. Metaanalysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008, 28:868-877.
44. McNicholl A.G., Linares P.M., Pérez Nyssen O., Calvet X., Gisbert J.P. Meta-analysis of studies comparing the first and new generation proton pump inhibitors in the eradication of Helicobacter pylori. Gastroenterology 2012, 142(Suppl 1):S-481.
45. Greenberg E.R., Anderson G.L., Morgan D.R., Torres J., Chey W.D., Bravo L.E., et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011, 378:507-514.
46. Herrero R., Salazar-Martínez E., Sexton R., Morgan D.R., Domínguez R., Torres J., et al. Predictors of success of Helicobacter pylori eradication treatment in a multicentric randomized clinical trial (SWOG S0701) in Latin America. Gastroenterology 2012, 142(Suppl 1):S-183.
47. Franceschi F., Tortora A., Campanale M., Bertucci F., Pecere S., Gerardi V., et al. High dose amoxicillin-based first line regimen compared to sequential therapy in the eradication of H. pylori infection. Gastroenterology 2012, 142(Suppl 1):S-487.
48. Gene E., Calvet X., Azagra R., Gisbert J.P. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a metaanalysis. Aliment Pharmacol Ther 2003, 17:1137-1143.
49. Venerito M., Krieger T., Ecker T., Malfertheiner P. Superiority of bismuth-based quadruple therapy vs. standard triple therapy for empiric primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability. Gastroenterology 2012, 142(Suppl 1):S-487.
50. Vakil N.B., Fiorini G. What should the replacement for triple therapy be? a systematic review and meta-analysis of competing H. pylori therapies. Gastroenterology 2012, 142(Suppl 1):S-485.
51. Gisbert J.P., Bonfil X. Systematic reviews and meta-analyses: how should they be performed, evaluated and used?. Gastroenterol Hepatol 2004, 27:129-149.
52. Gisbert J.P., Calvet X., O'Connor A., Megraud F., O'Morain C.A. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010, 44:313-325.
53. Vaira D., Gatta L., Vakil N.B., Fiorini G., Castelli V., Saracino I.M., et al. More than 90% eradication rate with sequential therapy in clarithromycin resistant Helicobacter pylori patients: a prospective uncontrolled study. Gastroenterology 2012, 142(Suppl 1):S-485.
54. Gisbert J.P. The recurrence of Helicobacter pylori infection: incidence and variables influencing it. A critical review. Am J Gastroenterol 2005, 100:2083-2099.
55. Molina-Infante J., Pérez-Gallardo B., Fernández-Bermejo M., Hernández-Alonso M., Vinagre G., Dueñas C., et al. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2010, 31:1077-1084.
56. McNicholl A.G., Marín A.C., Molina-Infante J., Castro-Fernández M., Barrio J., Ducons J., Phase I.V., et al. prospective, randomized and comparative study between sequential and concomitant therapy for Helicobacter pylori eradication in routine clinical practice Interim results. Gastroenterology 2012, 142(Suppl 1):S-485.
57. Kim N., Hee Nam R., Yeon Kim J., Kyoung Lee M., Won Lee J. Comparison of ten-day, fifteen-day sequential therapy and protonpump inhibitor-based triple therapy in Korea: a prospective randomized study. Gastroenterology 2012, 142(Suppl 1):S-484.
58. Chung J.W., Kul Jung Y., Jae Kim Y., Ho Kim J., Jeong J.Y., Mi Lee S., et al. 10-day sequential versus triple therapy for H. pylori eradication in peptic ulcer patients: prospective randomized trial. Gastroenterology 2012, 142(Suppl 1):S-488.
59. Gatta L., Ricci C., Castelli V., Zullo A., Vaira D. A systematic review and meta-analysis of performance of sequential therapy in clinical trial on naïve adult and children infected with H. pylori. Gastroenterology 2012, 142(Suppl 1):S-484-S-485.
60. Essa A.S., Kramer J.R., Graham D.Y., Treiber G. Meta-analysis: fourdrug, three-antibiotic, non-bismuth-containing " concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter 2009, 14:109-118.
61. Gisbert J.P., Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012, 5:23-34.
62. Gisbert J.P., Calvet X. Non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther 2011, 34:604-617.
63. Choi C., Lee D.H., Chon I., Park H.K. The two weeks sequential therapy and the concomitant therapy for Helicobacter pylori eradication were effective as a first line therapy in Korea: a preliminary report. Gastroenterology 2012, 142(Suppl 1):S-740.
64. Wu D.C., Hsu P.I., Wu J.Y., Opekun A.R., Kuo C.H., Wu I.C., et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of H. pylori infection. Clin Gastroenterol Hepatol 2010, 8:36-41. e1.
65. Huang Y.K., Wu M.C., Wang S.S., Kuo C.H., Lee Y.C., Chang L.L., et al. Lansoprazole-based sequential and concomitant therapy for the first-line Helicobacter pylori eradication. J Dig Dis 2012, 13:232-238.
66. Hsu P.I., Wu D.C., Wu J.Y., Graham D.Y. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 2011, 16:139-145.
67. Wu J.Y., Hsu P.I., Wu D.C., Graham D. Optimal duration to maintain greater than 95% eradication rate in hybrid therapy for H. pylori. Gastroenterology 2012, 142(Suppl 1):S-484.
68. Calvino-Fernández M., García-Fresnadillo D., Benito-Martínez S., McNicholl A.G., Gisbert J.P., Parra Cid T. Photodynamic therapy: an alternative strategy against Helicobacter pylori. Gastroenterology 2012, 142(Suppl 1):S-486.
69. Efrati C., Nicolini G., Cannaviello C. Lactobacillus reuteri improves the eradication rate of Helicobacter pylori. Gastroenterology 2012, 142(Suppl 1):S-483.
70. Barry D.P., Asim M., Tejera-Hernández N., Gordon O.N., Qian X., Denney K.A., et al. Curcumin encompassed in phosphatidylcholine liposomes has enhanced effectiveness as an inhibitor of Helicobacter pylori growth and pathogenesis. Gastroenterology 2012, 142(Suppl 1):S-488.
71. Gisbert J.P., Pérez Aisa A., Castro-Fernández M., Barrio J., Rodrigo L., Cosme A., et al. Helicobacter pylori first-line treatment with clarithromycin and metronidazole in patients allergic to penicillin: is it an acceptable option?. Gastroenterology 2012, 142(Suppl 1):S-482.
72. Michopoulos S., Zampeli E., Anapliotis P., Mavros M., Giannopoulos C., Xourafas V., et al. Substitution of tetracycline by amoxicillin in second-line Helicobacter pylori treatment conveys comparable success rates. Gastroenterology 2012, 142(Suppl 1):S-487.
73. Hu H.M., Hsu P.I., Chuah S.K., Liu M.K., Kuo F.C., Kuo C.H., et al. Amoxicillin in replacement for bismuth subcitrate offers similar Helicobacter pylori eradiation response in second-line rabeprazole- based quadruple therapy. Gastroenterology 2012, 142(Suppl 1):S-485.
74. Gisbert J.P., Morena F. Systematic review and meta-analysis: levofloxacin- based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006, 23:35-44.
75. Marín A.C., McNicholl A.G., Gisbert J.P. Meta-analysis of levofloxacin- containing triple therapy vs. bismuth-containing quadruple therapy as second-line treatment in the eradication of Helicobacter pylori. Gastroenterology 2012, 142(Suppl 1):S-483.
76. Chuah S.K., Kuo C.M., Hsu P.I., Wu D.C. Second-line anti-Helicobacter pylori rescue therapy using extended length of 14-days levofloxacin- based regimen - a prospective randomized trial. Gastroenterology 2012, 142(Suppl 1):S-486.
77. Gisbert J.P., Pérez Aisa A., Bermejo F., Castro-Fernández M., Almela P., Barrio J., et al. Second-line rescue therapy with levofloxacin after failure of treatment to eradicate Helicobacter pylori infection: time trends in a Spanish multicenter study of 1,000 patients. Gastroenterology 2012, 142(Suppl 1):S-481.
78. Miehlke S., Rücker G., Krasz S., Morgner A., Labenz J., Metaanalysis: moxifloxacin triple therapy for first-line and rescue treatment of Helicobacter pylori infection. Gastroenterology 2012, 142(Suppl 1):S-483.
79. Gisbert J.P., Marín A.C., Molina-Infante J. Second-line rescue triple therapy with levofloxacin after failure of quadruple nonbismuth " sequential" or " concomitant" treatment. Gastroenterology 2012, 142(Suppl 1):S-482.
80. Hyun Chung K., Ho Lee D., Kim N., Min Shin C., Hyeok Hwang J., Hyub Lee S., et al. Efficacy of second-line treatment for Helicobacter pylori infection: moxifloxacin-containing triple therapy vs. bismuth-containing quadruple therapy. Gastroenterology 2012, 142(Suppl 1):S-483.
81. Gisbert J.P., Castro-Fernandez M., Bermejo F., Perez-Aisa A., Ducons J., Fernandez-Bermejo M., et al. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. Am J Gastroenterol 2006, 101:243-247. Feb.
82. Gisbert J.P., Castro-Fernández M., Pérez Aisa A., Bermejo F., Ducons J., Fernández Bermejo M., et al. Third-line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infection. Gastroenterology 2012, 142(Suppl 1):S-481.
83. Kato C., Sugiyama T., Fujinami H., Kajiura S., Nshikawa J., Minemura M., et al. Third-line eradication therapy with sitafloxacin (STFX) for Helicobacter pylori infection and predictive factors for successful eradication. Gastroenterology 2012, 142(Suppl 1):S-579.
84. Furuta T., Sugimoto M., Nishino M., Yamade M., Uotani T., Sahara S., et al. Comparison of three third-line rescue triple regimens for Helicobacter pylori infection in Japan. Gastroenterology 2012, 142(Suppl 1):S-486.
85. Gisbert J.P., Calvet X. Rifabutin in the treatment of refractory Helicobacter pylori infection: a review. Gastroenterology 2012, 142(Suppl 1):S-481.
86. Gisbert J.P., Castro-Fernández M., Pérez Aisa A., Cosme A., Molina-Infante J., Rodrigo L., et al. Fourth-line rescue therapy with rifabutin in patients with three H. pylori eradication failures. Gastroenterology 2012, 142(Suppl 1):S-482.
87. Gisbert J.P., Castro-Fernández M., Pérez-Aisa A., Cosme A., Molina-Infante J., Rodrigo L., et al. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. Aliment Pharmacol Ther 2012, 35:941-947.
88. Malfertheiner P., Selgrad M., Wex T., Bornschein J., Palla E., Del Giudice G., et al. Efficacy of an investigational recombinant antigen based vaccine against a CagA H. pylori infectious challenge in healthy volunteers. Gastroenterology 2012, 142(Suppl 1):S-184.
89. Gisbert J.P., Luna M., Gómez B., Herrerías J.M., Mones J., Castro-Fernández M., et al. Recurrence of Helicobacter pylori infection after several eradication therapies: long-term follow-up of 1,000 patients. Aliment Pharmacol Ther 2006, 23:713-719.
90. Gisbert J.P., García-Gravalos R., Calvet X., Cosme A., Almela P., Benages A., et al. Eradication of Helicobacter pylori for the prevention of peptic ulcer rebleeding: Long-term follow-up study of 1,000 patients. Gastroenterology 2012, 142(Suppl 1):S-489.
91. Gisbert J.P., Calvet X., Cosme A., Almela P., Feu F., Bory F., et al. Long-term follow-up of 1,000 patients cured of Helicobacter pylori infection following an episode of peptic ulcer bleeding. Am J Gastroenterol 2012, 107:1197-1204.
92. Young Kim S., Jin Hyun J., Woo Jung S., Seol Koo J., Seon Choung R., Joon Yim H., et al. Helicobacter pylori recurrence after eradication therapy in Korea. Gastroenterology 2012, 142(Suppl 1):S-480-S-481.
93. Abid S., Yakoob J., Jafri W.S., Abbas Z., Mumtaz K., Hamid S.S., et al. High clarithromycin resistance and a low rate of recurrence and reinfection of Helicobacter pylori infection in Pakistan. Gastroenterology 2012, 142(Suppl 1):S-488.
94. Morgan D.R., Torres J., Greenberg E.R., Sexton R., Salazar-Martínez E., Domínguez R., et al. H. pylori recurrence one year after eradication treatment in a population randomized trial (SWOG S0701) in seven Latin American sites. Gastroenterology 2012, 142(Suppl 1):S-478-S-479.